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Ebola virus disease case definition is a crucial surveillance tool to detect suspected cases for referral 
and as a screening tool for clinicians to support admission and laboratory testing decisions at Ebola 
health facilities. We aimed to assess the performance of the WHO Ebola virus disease case definitions 
and other screening scores. 
Methods 
In this systematic review and meta-analysis, we searched PubMed, Scopus, Embase, and Web of 
Science for studies published in English between June 13, 1978, and Jan 14, 2020. We included studies 
that estimated the sensitivity and specificity of WHO Ebola virus disease case definitions, clinical and 
epidemiological characteristics (symptoms at admission and contact history), and predictive risk scores 
against the reference standard (laboratory-confirmed Ebola virus disease). Summary estimates of 
sensitivity and specificity were calculated using bivariate and hierarchical summary receiver operating 
characteristic (when four or more studies provided data) or random-effects meta-analysis (fewer than 
four studies provided data). 
Findings  
We identified 2493 publications, of which 14 studies from four countries (Sierra Leone, Guinea, 
Liberia, and Angola) were included in the analysis. 12021 people with suspected disease were included, 
of whom 4874 were confirmed as positive for Ebola virus infection. Six studies explored the 
performance of WHO case definitions in non-paediatric populations, and in all of these studies, 
suspected and probable cases were combined and could not be disaggregated for analysis. The pooled 
sensitivity of the WHO Ebola virus disease case definitions from these studies was 81·5% (95% CI 
74·1–87·2) and pooled specificity was 35·7% (28·5–43·6). History of contact or epidemiological link 
was a key predictor for the WHO case definitions (seven studies) and for risk scores (six studies). The 
most sensitive symptom was intense fatigue (79·0% [95% CI 74·4–83·0]), assessed in seven studies, 
and the least sensitive symptom was pain behind the eyes (1·0% [0·0–7·0]), assessed in three studies. 
The performance of fever as a symptom varied depending on the cut-off used to define fever. 
Interpretation 
WHO Ebola virus disease case definitions perform sub-optimally to identify cases at both community 
level and during triage at Ebola health facilities. Inclusion of intense fatigue as a key symptom and 
contact history could improve the performance of case definitions, but implementation of these changes 









Ebola virus disease case definition is a crucial surveillance tool to detect suspected cases for referral 
and as a screening tool for clinicians to support admission and laboratory testing decisions at Ebola 
health facilities. However, there have been long-standing concerns about the poor performance of the 
WHO Ebola virus disease case definitions, including the inability to distinguish Ebola virus disease 
from common diseases such as malaria and typhoid fever (1-3). 
The scale of the 2014–16 west African Ebola epidemic further challenged the operational use and 
validity of the WHO case definitions in detecting suspected cases at the community level and allocating 
patients appropriately to high-risk or low-risk wards for testing at specialised isolation centres(4). 
Consequently, during and since this epidemic, organisations involved in the Ebola virus disease 
response have estimated the sensitivity and specificity of the WHO case definitions and its constituent 
symptoms and signs, and developed alternative definitions and risk scores to identify clinical and 
epidemiological factors that could predict infection under outbreak conditions (5, 6). Discordance on the 
use of WHO Ebola virus disease case definitions with consequent delay on outbreak control and 
community disengagement have been reported in west Africa and, in the current outbreak, in the 
Democratic Republic of the Congo along with its bordering countries (7-9). 
However, the operational use and performance of those definitions and risk scores has not been 
rigorously evaluated. Such an evaluation is needed to guide communities and public health practitioners 
to improve the effectiveness and efficiency of identification and management of suspected cases during 
Ebola virus disease responses. 
We aimed to assess the performance of the WHO Ebola virus disease case definitions and other clinical 
and epidemiological characteristics, such as symptoms and signs at admission and contact history, as 




Search strategy and selection criteria  
For this systematic review and meta-analysis, we searched PubMed, Scopus, Embase, and Web of 
Science, without regional restrictions, for studies in English published between June 13, 1978 (when 
the first Ebola virus disease outbreaks were reported on), and Jan 14, 2020 (10,11) We also endeavoured 
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to capture data on the current outbreak of Ebola virus disease in the Democratic Republic of the Congo 
by contacting relevant people involved in the response. 
The search terms included “Ebola”, “EVD infection”, “case definition”, “admission symptoms”, 
“sensitivity”, “specificity”, “likelihood”, “score”, “classification”, “validity” and “performance” 
(Appendix, pp 5-6). 
We included observational retrospective studies that estimated the sensitivity and specificity of WHO 
Ebola virus disease case definitions and other clinical and epidemiological characteristics (symptoms 
and signs at admission and contact history) against the reference standard (laboratory confirmation of 
Ebola virus infection), and studies that developed, or externally validated, predictive risk scores (based 
on a combination of symptoms and signs, and epidemiological information) to predict the risk of being 
positive for Ebola virus. 
We also included studies looking at sensitivity and specificity of WHO case definitions for Ebola or 
Marburg virus infections because they belong to the same family of viruses (Filoviridae) and share the 
same case definitions, and the reference standard is laboratory confirmation of infection (12). 
We excluded studies on the sensitivity and specificity of diagnostic tests, animal and vaccine studies, 
studies of survivors of Ebola virus disease, and studies on predictors of outcomes or severity of Ebola 
virus disease, community surveillance, and outbreak and clinical management. Studies specifically on 
frequency of symptoms at admission were also excluded as a previous review exists (13). 
Two reviewers (GC and FT) independently screened all titles and abstracts to identify those meeting 
the selection criteria, and a third author (LI) arbitrated for studies without consensus. A full-text review 
was then done for these articles, and their bibliographies were assessed for other eligible studies. We 
extracted data on author, year of publication, country, virus, period of data collection, study design, 
study objective, outcomes measured, setting in which data were collected (eg, Ebola treatment centres), 
age of population included in the study, study size including number of patients who were negative and 
positive for Ebola virus, diagnostic method, limitation of individual studies, and performance of the 
WHO Ebola virus disease case definitions, and individual symptoms and signs, and epidemiological 
links or contact history with known patients with Ebola virus disease. 
Performance data extracted included sensitivity, specificity, predictive values and risk score, and area 
under the receiver operating characteristic (ROC) curve (AUC). We developed a spreadsheet to compile 
extracted data based on the Cochrane data tool (14). The primary data extracted from each article were 
checked by a second researcher (FT). No protocol was developed for this study. 
WHO Ebola virus disease case definitions were used to define suspected, probable, and confirmed 
cases, which varied by context and period of outbreak. In 2014 in Sierra Leone, WHO included 
miscarriage as an additional symptom (eg, abdominal pain) or sign (eg, vaginal bleeding) to the existing 
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definitions (12,15) For paediatric populations, the modified WHO case definition used in Sierra Leone 
was evaluated (figure 1) (15). 
Data analysis  
We derived the numbers of true positive, false negative, true negative, and false positive cases in each 
study using data provided in each article for each symptom and sign, and WHO Ebola virus disease 
case definition. Sensitivity and specificity are correlated, and univariate measures of heterogeneity, such 
as I², are not suitable to report heterogeneity in diagnostic test accuracy reviews (16). We used bivariate 
and hierarchical summary ROC (HSROC) models for meta-analysis (17,18). 
The bivariate model provides estimation of a summary of sensitivity and specificity, whereas the 
HSROC model provides the estimation of a summary curve from studies that have used different 
thresholds, the 95% confidence region for the summary point, and the 95% prediction region. The 
prediction region graphically illustrates between-study heterogeneity as well as the bivariate 
relationship between sensitivity and specificity (19). Only studies that used comparable thresholds, 
symptoms and signs, or definitions were combined using these methods. 
Given that HSROC models cannot be fitted when there are data from fewer than four studies, for some 
symptoms and signs we did a random-effects meta-analysis to calculate pooled estimates for sensitivity 
and specificity (20 ) .Compared with bivariate and hierarchical models, pooled estimation from random-
effects meta-analysis could slightly overestimate point estimation, so estimates from the random-effects 
model are provided for completeness. 
We summarised, without any further re-analysis, studies that developed or externally validated risk 
scores for predicting Ebola virus infection. Scores were used to identify individuals with a higher or 
lower risk of Ebola virus infection during screening at Ebola health facilities. To obtain the risk scores, 
these studies used the regression coefficients of independent risks obtained by multivariable logistic 
regression against Ebola virus infection and then converted regression coefficients into an integer-based 
point-scoring system. Reviewed studies assigned positive and negative risk scores with calculated AUC 
to epidemiological, demographic, and clinical characteristics. Positive values indicated higher risk of 
Ebola virus infection and negative values indicated higher risk of another infection such as malaria or 
typhoid. 
Values assigned to the risk score varied by study; therefore, a meta-analysis of risk scores was not done, 
but instead evidence was systematically reviewed. For comparability, we reclassified the risk scores 
reported in the included studies into categories, from very low risk to very high risk (appendix p 7). 
STATA 15 was used for statistical analysis.  
PRISMA guidelines for Diagnostic Test Accuracy Studies (PRISMA-DTA) were followed (appendix 
pp 2–4) (21). 
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Role of the funding source  
GC, KL, AS, and JG were employed by the funder, and participated in planning the study, carrying out 
the research, and writing the report. The funder of the study had no further role in study design, data 
collection, data analysis, data interpretation, or writing of the report. The corresponding author had full 
access to all the data in the study and had final responsibility for the decision to submit for publication. 
Results 
 
Of the 2493 studies initially screened using the article title, 143 were deemed to be potentially eligible 
on the basis of the abstract, and their full-text articles were assessed. Of these studies, 18 met the 
inclusion criteria, but three were excluded because data on sensitivity and specificity could not be 
extrapolated (appendix p 8). One was excluded because it is yet unpublished (FG). Of the 14 included 
studies, 11 were full manuscripts (5,6,22,24,25,27,29–33), one a letter (28) , one an oral plenary abstract (26) , and 
one a conference poster (23) (the author of this poster was also contacted and they provided an abstract 
with additional data [Kuehne A, Epicentre, Paris, France, personal communication]; table 1). 13 studies 
were published between 2015 and 2019 and assessed Ebola virus disease in the west Africa outbreak 
(seven in Sierra Leone (5,6,25,26,30,32,33), four in Guinea (24,27,28,31) , and two in Liberia (23,29) ). The remaining 
article was published in May, 2010, assessing Marburg virus in Angola.(22) . 
Overall, 12 021 people with suspected disease were included, of whom 4874 were confirmed as positive 
for Ebola virus infection. Study populations varied from 75 to about 2847 (table 1). All studies, apart 
from the national surveillance study, included patients who presented alive to health facilities for 
assessment. The national surveillance study included all cases (suspected, probable, and confirmed), 
including patients both alive and deceased, identified in both the community and health facilities. Eight 
studies’ data were from single Ebola treatment centres (23,27–33), with the remaining using a national 
surveillance list (24), three from Ebola holding units (5,25,26), and two from hospitals screening patients 
for Ebola virus disease while still functioning as general health facilities (6,22). All studies covered 
distinct patient groups from different periods and geographical areas, except for two studies from 
Guinea (24,27). Although these two studies covered overlapping patient groups, they reported on different 
clinical and epidemiological characteristics (WHO case definition performance vs symptom 
performance) (24,27). 
All selected manuscripts analysed all ages combined, except one author who assessed, in two different 
studies, the sensitivity and specificity of 2014 WHO Ebola case definitions and also developed a risk 
score specifically for the paediatric population (younger than 13 years) (25,26). 
Six studies explored the performance of a WHO case definition in non-paediatric populations (5,22,24,29–
31) . In all of these studies, suspected and probable cases were combined and could not be disaggregated 
for analysis. The following results therefore apply to this combined group of suspected and probable 
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cases. The pooled sensitivity was 81·5% (95% CI 74·1–87·2) and pooled specificity was 35·7% (28·5–
43·6; figure 2). One study assessed WHO 2014 case definitions for a paediatric population (younger 
than 13 years old); the sensitivity was 98·0% (95% CI 95·0–99·0) and specificity was 5·0% (3·0–7·0) 
(25). 
When WHO subdefinitions were assessed, history of contact and symptoms had high specificity 
compared with clinical symptoms alone, ranging from 62·3% (95% CI 49·8–73·5) to 94·4% (95% CI 
not provided in original paper; table 2). The highest sensitivity (100·0%) was documented for the WHO 
subdefinitions in which fever was not mandatory. Among studies using clinical symptoms and signs 
alone, the definition including three or more symptoms (intense fatigue, confusion, conjunctivitis, hiccups, 
diarrhoea, and vomiting) had the highest specificity (79·1% [95% CI not provided in original paper]). 
Unexplained death had high specificity (92·8% [95% CI not provided in original paper]) but the lowest 
sensitivity (14·2% [95% CI not provided in original paper]; table 2). 
For children, the highest specificity (97·0% [95% CI not provided in original paper]) was with a case 
definition of contact, fever, and conjunctivitis, or contact, fever, anorexia, and two of abdominal pain, 
diarrhoea, or male sex (older than 2 years; table 2) (26). 
Seven articles developed a risk score (22,23,25,29,31–33) and among those five (25,29,31–33) did an internal 
validation (using bootstrap or test and training methods) and one assessed a risk score according to 
outbreak prevalence in a paediatric population (25). An eighth study (28) externally validated the score 
developed by Oza and colleagues (33) without developing an alternative score. Of the 44 potential 
predictors of Ebola virus infection included across the seven studies that developed risk scores, 20 were 
found to be positive or negative predictors (figure 3). The score system ranged from very low to very high 
risk, with intermediate categories varying across studies (appendix p 7). 
One study created a malaria sensitive score aiming to discriminate between Ebola virus infection and 
malaria infection, which indicated a predictor power of 89·6% (95% CI 86–93) to discriminate Ebola 
virus positive versus negative, reaching a discrimination power of 98·5% (95% CI not provided in original 
paper) during the malaria season (32). The same study obtained similar results (AUC 76·8% [95% CI not 
provided in original paper] vs 75·0% [70·0–80·0]), when externally validating the scores developed by 
Levine and colleagues (29,32). 
The study validating Oza and colleagues’ algorithm found poorer performance in their cohort (AUC 58% 
[95% CI 56–61] vs 83·0% [79–86]) (28,33). 
The highest performing score was developed by Hartley and colleagues (32), a key difference being referral 
time (figure 3). For the adult population (six studies 22,23,29,31–33), a positive risk score for infection was 
associated in more than one study with each of the following five characteristics: epidemiological link 
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(eg, history of contact), diarrhoea, conjunctivitis, unexplained bleeding, difficulty swallowing (also called 
dysphagia; figure 3).  
Fever was assessed at different thresholds (>38·0°C or ≥38·5°C), and inclusion of fever in the final 
predictive score was only reported by two studies (31,32) (figure 3). Discordant values were assigned across 
studies (either positive or negative) for anorexia or loss of appetite, muscle pain (also called myalgia), and 
abdominal pain. 
For the paediatric population (one study 25), positive predictors were age (2 years or older), sex (male), 
epid-emiological link, diarrhoea, conjunctivitis, fever (>38·0°C), anorexia or loss of appetite, and 
abdominal pain. Negative predictors were difficulty swallowing, rash, headache, and difficulty breathing 
(also called dyspnoea; figure 3). The same study compared two different time periods over the Ebola virus 
disease 2014–16 outbreak in Sierra Leone (high prevalence in October, 2014 [77% of suspected cases 
testing positive], and low prevalence in March, 2015 [4% of suspect cases testing positive]): a low cutoff 
for the risk score (with high sensitivity) performed better at periods of high prevalence transmission, and 
a high cutoff with high specificity performed better during low prevalence (25). Similarly, the positive 
predictive value decreased from 93% to 31%, and the negative predictive value increased from 23% to 
90% when comparing high (early) to low (late) transmission periods in the Ebola virus disease outbreak 
in another study in Liberia in an all ages population (23).     
Eight studies measured sensitivity and specificity of individual symptoms at admission, assessing a total 
of 35 symptoms (5,22–24,27,29–31). The pooled sensitivity per symptom ranged from 79·0% (95% CI 74·4–
83·0) for intense fatigue (seven studies) to 1·0% (0·0–7·0) for pain behind the eyes (three studies). By 
contrast, the pooled specificity ranged from 98·0% (95% CI 91·0–100·0) for pain behind the eyes to 
32·3% (95% CI 25·8–39·4) for intense fatigue (appendix p 9). 
Haemorrhagic symptoms and signs were the most specific indicator of infection. Other symptoms and 
signs with high specificity included confusion, coma, hiccups, rash, and sore throat with specificity 
ranging from 92·0% (95% CI 91·0–94·0) for hiccups to 97·8% (95% CI 95·2–99·0) for rash (appendix p 
9). Performance of fever was assessed by seven studies, but each one used a different definition of fever 
(5,22,23,27,29–31). The optimal performance (definition that achieved best balance between maximising 
sensitivity vs maximising specificity) for fever was a threshold at ≥38·5°C (sensitivity 80·2% [95% CI 
69·2–88·2]; specificity 82·6% [71·2–90·3]; table 3).31 In the random- effects analysis, a threshold at 
greater than 38·0°C (three studies 22,27,29) gave a pooled sensitivity of 80·0% (95% CI 69·0–90·0) and 
specificity of 25·0% (17·0–33·0; table 3). 
Seven studies assessed sensitivity and specificity of an epidemiological link (5,22–24,29–31). Across these 
studies, the sensitivity of an epidemiological link ranged from 21·6% (95% 17·9–25·6) to 100·0% and 
specificity ranged from 29·0% (95% CI 19·0–41·3) to 86·0% (95% CI 74·0–94·0). The most sensitive 
definition was history of contact with a person with confirmed Ebola virus infection (100·0%; table 3). 
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The most specific definition was direct contact with an individual potentially infected with Marburg virus 
or his or her body fluids, or direct contact during funeral practices (22). 
Discussion 
 
Our results indicate that, for all ages combined, the WHO case definitions have a sensitivity of 81·5% 
and a specificity of 35·7%. The sensitivity is not high enough to achieve acceptable false negative rates, 
particularly in low-prevalence settings, the primary requirement for community-based screening. The 
low specificity results in high numbers of false positives and thus potentially unnecessary admissions 
to Ebola treatment centres, with associated risk of nosocomial transmission and costs of managing 
suspected cases (1). As a consequence, a large number of people who do not have Ebola virus disease 
will experience unnecessary invasive procedures, risk of being infected with Ebola virus, isolation from 
family, fear of being stigmatised, and delay to appropriate care, and community mistrust in response 
activities will increase. 
 
In our meta-analysis, fever had low specificity (25·0%), except for when defined as a threshold at 
38·5°C or more (82·6%), and the WHO case subdefinition had 100% sensitivity only when fever was 
not a mandatory criterion. In the risk score systematic review, the association of fever with Ebola virus 
infection was not consistent across studies, with only two studies including it in the final predictive 
score. Presence of fever is likely to be related to the stage of infection at admission, with previous 
studies reporting absence of fever in a large proportion of suspected cases at admission (34). This finding 
is consistent with a recent Ebola seminar reporting that fever was absent in at least 10% of the cases in 
the west Africa outbreak (35). 
 
Therefore, exclusion of fever from the case definition at the community level is likely to increase the 
sensitivity of the case definition. Intense fatigue was the most sensitive symptom (79·0%) that could be 
used at the community level to facilitate early referral of suspected cases and prevent community 
transmission. 
 
The meta-analysis did not identify any individual symptom or sign having an optimal trade-off between 
sensitivity and specificity. Conjunctivitis, unexplained bleeding, difficulty swallowing, and diarrhoea 
were individual symptoms and signs with the best discriminatory accuracy in the studies that explored 
risk score for the all-age population and with the exception of diarrhoea all had high specificity (>80%) 
in the studies that explored their performance. However, these symptoms and signs could also be a 
proxy for late-stage disease when the virus infects endothelial cells, compromising vascular integrity, 
with massive tissue injury resulting in disseminated intravascular coagulopathy with risk of thrombosis, 
bleeding, and damage to the adrenal glands and gastrointestinal system (36–38). These symptoms and 
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signs could enable health practitioners to prioritise patients for admission to an Ebola treatment centre 
when resources are scarce but are less useful at the community level because they appear at a late stage 
of the disease when transmission risk is the highest. 
 
None of the studies assessed miscarriage, despite it being included in the December, 2014, WHO case 
definition (15) . History of miscarriage and other associated pregnancy complications (eg, stillbirth) could 
help to identify cases that can be a major source of nosocomial transmission in general health facilities. 
(39) . 
Although only one study focused on a paediatric population, this study used data from 11 Ebola holding 
units and included a large population of children (1006), providing useful guidance for this age group 
(26).  
 
The WHO paediatric definition had very high sensitivity (98·0%) but very poor specificity (5·0%). 
When the same authors assessed a WHO subdefinition (including contact, fever, and conjunctivitis, or 
contact, fever, anorexia, and two of abdominal pain, diarrhoea, or male sex [older than 2 years]), the 
sensitivity dropped markedly to 23·0% but the specificity improved to 97·0%. The optimal fever 
temperature cutoff for the paediatric population was not explored. However, in another study of a 
paediatric population of patients with confirmed Ebola virus disease admitted to one Ebola treatment 
centre in Sierra Leone, 25% of children aged 5 years and younger were afebrile (40). This difference 
might be due to several factors: how fever was assessed (either reported in their history or measured at 
admission), age groups included (younger than 13 years vs younger than 5 years), period of data 
collection (August–March, 2015, vs June–Dec, 2014) when seasonality of other febrile illnesses could 
have influenced fever prevalence, background Ebola virus transmission rates, and viraemia at admission 
and time since onset of symptoms. 
 
The paediatric analysis did not explore sensitivity and specificity of individual symptoms and signs at 
admission for children. Alongside the fact that they might have different clinical presentations 
compared with adults, children are more likely to experience adverse outcomes from Ebola virus disease 
and are less able to report symptoms and history of contact. 
 
Similarly, pregnant women with non-Ebola virus disease-related complications usually present with 
symptoms (such as bleeding and abdominal pain) that mimic Ebola virus infection (39). As suggested 
elsewhere, the paediatric and pregnant women populations might require adaptation of case definitions 
that take into account their specific characteristics. (41–43). None of the selected manuscripts explored the 
performance of WHO Ebola case definitions among pregnant women. Therefore, further evidence 
specifically applicable to children and pregnant women is required to develop appropriate tools for 
screening for Ebola virus disease in these populations.  
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Reported history of contact was a strong predictor for paediatric and adult populations, often performing 
better than many of the clinical symptoms included in accepted case definitions, as also reported by 
other studies (44). However, it is likely that this is an underestimate of the potential performance of actual 
contact history in screening for Ebola virus disease. 
Levels of disclosure of self-reported clinical information and contact history depend on community 
engagement with intervention strategies, including trust in the health-care provider. Therefore, to 
improve WHO case definition performance, effective and trusted collaboration with communities is 
essential to ensure reliable understanding and reporting of such crucial epidemiological information. 
Equally, it is the responsibility of response agencies to understand the underlying pattern of Ebola virus 
transmission, local traditions, coping mechanisms, and family dynamics in order to identify people at 
risk of infection. Genetic sequencing has also been put forward as a tool for identifying chains of 
transmission when contact history is unknown (45).  
 
One of the limitations in interpreting the results of this meta-analysis is that all the evidence reviewed, 
apart from the national surveillance study, came from patients triaged at health facilities or Ebola 
isolation centres. Thus, this meta-analysis might represent only cases with severe symptoms, limiting 
generalisability to the performance of these screening criteria at the community level and in early stages 
of disease. Second, there was significant heterogeneity between selected studies, and considerable 
variation in the quality of data on clinical symptoms and recollection of patients’ history, with different 
variables and thresholds used in each study, and limited data on co-infection. For example, fever is a 
key symptom in the WHO case definitions, but different temperatures were used to define fever, which 
could explain the between-study heterogeneity. Inconsistency on thresholds for fever and the decision 
to include fever or not have been reported in the Democratic Republic of the Congo and in four 
neighbouring countries (9). 
 
For the two studies with overlapping patient populations, performance of WHO case definitions was 
assessed only using national surveillance data, with Ebola treatment centre data for these patients being 
assessed for only individual symptoms or WHO subdefinitions. These two studies were therefore not 
included together in pooled estimations, so the cohort overlap would not have affected results. 
Individual studies mentioned small sample size and poor quality of data as part of their limitations. 
A range of contextual factors related to study setting will affect the performance of Ebola virus disease 
case definitions, including seasonally occurring diseases such as malaria and Lassa fever, which have a 
similar clinical presentation to Ebola virus disease. Such factors will affect the generalisability of our 
findings to other settings. In addition, only two of the recommended risk scores were externally 
validated (28,32) , limiting the generalisability of those scores because performance appears to vary across 




Finally, there is potential for publication language bias because we considered only studies in English. 
However, for Guinea, a French-speaking country, we included data from national surveillance and two 
major Ebola treatment centres; therefore, we consider that bias due to language restrictions was 
minimised in our results. We included peer-reviewed abstract and poster data to capture data on 
paediatric populations and additional evidence for all age cohorts, and we sought unpublished evidence 
from French- speaking countries. 
This systematic review is relevant to inform public health practitioners in the current Ebola virus disease 
outbreak in the Democratic Republic of the Congo, in which only 8% of suspected cases isolated are 
confirmed, possibly because of inconsistent use of WHO case definition at community and health 
facility levels (46) . 
 
In conclusion, this first systematic review and meta-analysis of the strengths and limitations of the WHO 
Ebola virus disease case definitions highlights the need for further studies to assess consistent thresholds 
for fever, to explore viraemia and symptoms and signs at admission, and to externally validate risk 
scores for Ebola virus infection. The sensitivity and specificity of WHO Ebola case definitions could 
be improved by excluding fever and instead including both intense fatigue and history of contact. 
However, reliable disclosure of reported symptoms and history of contact requires effective 
collaboration with, and the trust of, affected communities. To achieve this trust and collaboration, 
responding organisations must recognise the paramount role of communities in controlling transmission 
and ending outbreaks. We also identified important gaps related to the paediatric and pregnant 
population, which must be addressed through future research. 
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Research in context 
 
Evidence before this study 
There have been long-standing concerns about the poor performance of WHO case definitions for Ebola 
virus disease, including their inability to distinguish Ebola virus infection from common tropical 
diseases. We did a systematic search of the scientific literature using PubMed, Scopus, Embase, and 
Web of Science, without regional restrictions, for research articles published in English between June 
13, 1978, and Jan 14, 2020. We used the search terms “Ebola”, “EVD infection”, “case definition”, 
“admission symptoms”, “sensitivity”, “specificity”, “likelihood”, “score”, “classification”, “validity” 
and “performance”. We also contacted relevant experts. We found that different organisations have 
attempted to assess the performance of WHO Ebola case definitions and developed alternative 
definitions and risk scores. However, there has been no systematic and rigorous evaluation of those 
studies. Such an evaluation is needed to guide communities and public health practitioners to improve 
the effectiveness and efficiency of identification and management of suspected cases during an Ebola 
virus disease outbreak. 
Added value of this study 
To our knowledge, this study is the first systematic review and meta-analysis that assesses the 
performance of the WHO Ebola virus disease case definitions, and other clinical and epidemiological 
characteristics such as symptoms and signs at admission and contact history, against the reference 
standard (laboratory confirmation of Ebola virus infection). Our analysis provides the most 
comprehensive evidence on the limitations of WHO case definitions and its constituent symptoms and 
signs, and predictive risk scores. We show that the WHO case definitions perform sub optimally to 
identify cases at both the community level and during triage at general and specialist health facilities. 
The performance of fever as a symptom varied depending on the cut off used to define fever. The most 
sensitive symptom was intense fatigue. History of contact was a key predictor for the WHO case 
definitions and for risk scores. This study identifies important gaps related to the paediatric and pregnant 
population and highlights the need to use consistent thresholds (e.g., for fever) to explore viraemia and 
symptoms at admission, and to externally validate risk scores for Ebola virus infection. 
Implications of all the available evidence 
Inclusion of intense fatigue as a key symptom could improve the sensitivity, the primary requirement 
for community-based screening, of WHO and alternative case definitions. Inclusion of contact history 
will improve specificity, resulting in a lower number of false positives and thus a lower number of 
unnecessary admissions to Ebola health facilities. These improvements will contribute to reduced 





Figure 1. WHO Ebola virus disease case definitions for all ages and the paediatric population 
 
 
WHO case definitions (August, 
2014) all ages12 
WHO case definition (December, 
2014) all ages in Sierra Leone15 
Late 2014 WHO case 
definition for paediat-
ric population in Si-
erra Leone15 
Suspected Any person, alive or dead, suffering 
or having suffered from sudden onset 
of high fever and having had contact: 
• a suspect, probable, or confirmed 
Ebola virus disease case 
• with a dead or sick animal (for Ebola) 
• a mine (for Marburg);  
OR 
any person with sudden onset of high 




• anorexia or loss of appetite 
• aching muscles or joints 
• stomach pain 
• difficulty swallowing 
• vomiting 
• difficulty breathing 
• diarrhoea 
• hiccups;  
OR 
any person with inexpli-
cable bleeding;  
OR 
any sudden, inexplicable death 
Any person having had contact with a clini-
cal case and presenting with acute fever 
(>38°C); 
OR 
having had contact with a clinical case 
(suspected, probable, or confirmed) and pre-
senting with three or more of the symptoms 
below; 
OR 
presenting with acute fever and presenting 
with three or more of the symptoms below: 
• headache 
• nausea or vomiting 
• loss of appetite 
• diarrhoea 
• intense fatigue 
• abdominal pain 
• generalised or articular pain 
• difficulty in swallowing 
• difficulty in breathing 
• hiccups 
• miscarriage;  
OR 
any person with unexplained bleeding or 
miscarriage; 
OR 
any unexplained death 
Any child with fe-
ver and either one 
symptom (in chil-
dren younger than 
5 years), two 
symptoms (in chil-
dren aged 5–12 
years), or more 
than three symp-
toms (in children 
older than 12 
years); for children 
younger than 1 
years old, maternal 
history is very im-
portant 
Confirmed Any suspected or probable cases with 
a positive laboratory result; laboratory-
confirmed cases must test positive for 
the virus antigen, either by detection of 
virus RNA by 
RT-PCR, or by detection of IgM anti-
bodies directed against  Marburg or 
Ebola 
Any person with a positive PCR test for 
Ebola or Marburg virus 
Any person with a posi-
tive PCR test for Ebola 
or Marburg virus 
Probable Any suspected case evaluated 
by a clinician;  
OR 
any deceased suspected case (where it 
has not been possible to collect speci-
mens for laboratory confirmation) 
having an epidemiological link with a 
confirmed case 
A suspect case that is known to have had 
contact with a known case (suspected, 
probable, or confirmed); 
OR 
any person who is, on clinical or epidemi-
ological grounds, very likely to have Ebola 
or Marburg 









 Table 1. Overview of articles included in the systematic review and meta-analysis  
  
Country Virus Period of Design Objective Outcomes Setting of Age of Patients positive Method (reference Limitations  
   data    data collection study for Ebola virus/ standard) and   
   collection     population total patients timing of Ebola   
          virus confirmatory   
          testing   
Roddy et al Angola Marburg March–July, Observational Evaluate the diagnostic Sensitivity and Screening at All ages 41/102 Quantitative PCR Small sample; only saw pa-
tients 
 
(2010)22   2005 retrospective validity of individual pa-
tient 
specificity of WHO one hospital   on admission at admission; data only cap-
tured 
 
    study of data clinical and epidemiologi-
cal 
case definition,     Marburg haemorrhagic fever;  
    at admission characteristics and WHO case     hospital-based data collec-
tion; 
 
     WHO-recommended case subdefinitions,     detailed data not available for 
all 
 
     definitions for Marburg symptoms at     Marburg haemorrhagic fever  
     haemorrhagic fever, and admission, and     cases; only presenting symp-
toms 
 
     develop a data-derived epidemiological     were recorded; highlights the  
     diagnostic algorithm for link; and risk score     necessity of collecting high-  
     Marburg haemorrhagic 
fever 
     quality clinical and  
     that improves the      epidemiological data during  
     WHO-recommended      outbreaks; over-representation 
of 
 
     definitions      individuals with more serious  
           symptoms that required hos-
pital 
 
           admission; no reported vali-
dation 
 
           (external or internal)  
Kuehne Liberia Ebola August, Observational Study the discriminative Sensitivity and One Ebola All ages 1235/1832 Quantitative PCR Reporting bias; poor data qual-
ity; 
 
et al   2014– retrospective accuracy (sensitivity, specificity of WHO treatment   on admission conference poster and abstract  
(2015)23   March, 2015 study of data attributable frequency, case subdefinitions, centre    data (Kuehne A, Epicentre, 
Paris, 
 
    at admission diagnostic test odds ratio, symptoms at     France, personal communica-
tion); 
 
    and clinical area under the receiver admission, and     no reported validation (exter-
nal or 
 
    results operating characteristic epidemiological     internal)  
     curve) of clinical signs, link; and risk score       
     contact history, and        
     combinations thereof        
Levine et al Liberia Ebola September, Observational Develop a clinical prediction Sensitivity and One Ebola All ages 160/382 Quantitative PCR Data collected only at admis-
sion, 
 
(2015)29   2014– retrospective model that can help to guide specificity of WHO treatment   on admission different stages of disease  
   January, study of data care for patients with case definition, centre    process; data might not be  
   2015 at admission suspected Ebola virus disease, symptoms at     representative of all patients  
16 
 
     provide specific parameters admission, and     with Ebola virus disease; 
poor 
 
     for isolation and admission 
to 
epidemiological     data quality; small sample;  
     treatment centres, and link; and risk score     patients pre-screened by 
Ebola 
 
     maximise resource use      treatment units (ambulance  
           travel); only assessed  
           14 variables; no reported  
           external validation, only in-
ternal 
 
          
 
 validation  
 Country Virus Period of data col-
lection  
Design Objective Outcomes Setting of data 
collection  






standard) and timing 
of Ebola virus con-
firmatory testing  
Limitations  
Lado et al Sierra Ebola May, 2014– Observational Identify clinical characteris-
tics 
Sensitivity and One Ebola All ages 464/724 Quantitative PCR Small sample; poor accuracy 
on 
 
(2015)5 Leone  December, retrospective that were predictive of Ebola   specificity of WHO holding unit   on admission reporting of symptoms and  
   2014 study of data virus disease diagnosis and case definition,     history; no access to patients 
who 
 
    at admission assess the accuracy of WHO case     chose not to present to hospital 
or 
 
     suspected Ebola virus disease subdefinition,     did not have access; no re-
ported 
 
     case definitions symptoms at     validation (external or inter-
nal) 
 
      admission, and       
      epidemiological link       
 Arranz et al (2016)30 Sierra Leone Ebola December, 2014– 
March, 2015 
Observational retrospec-
tive study of data at ad-
mission 
Compare the clinical charac-
teristics of  confirmed cases 
(patients with Ebola virus 
disease) and non-confirmed 
cases (patients without 
Ebola virus disease), assess 
the diagnostic validity of in-
itial symptoms used in 
WHO case definition to di-
agnose Ebola virus disease 
in a low-incidence situation 
Sensitivity and specificity of 
WHO case definition, WHO 
case subdefinition, symptoms 




 All ages 31/75 Quantitative PCR on 
admission 
Only data at admission; 
poor data quality; retrospec-
tive design; small sample; 
no reported validation (ex-
ternal or internal) 
 
 Loubet et al (2016)31 Guinea  Ebola  December, 2014– 
February, 2015 
Observational retro-




ical variables associated 
with Ebola virus disease di-
agnosis and to create, based 
on these variables, a predic-
tive score for identification 
of confirmed Ebola virus 
disease 
Sensitivity and specificity of 
WHO case definition, WHO 
case subdefinition, symp-
toms at admission, and epi-




All ages 76/145 Quantitative PCR on 
admission 
Data collected only at ad-
mission; poor data quality; 
retrospective design; pa-
tients included might have 
been reluctant to come to 
the Ebola treatment centre, 
and thus were more likely to 
present severe clinical 
presentation with late symp-
toms; temperature taking 
might be affected by several 
factors; small sample size; 
anorexia and temperature 




were associated with an in-
creased likelihood of Ebola 
virus disease) are not easy to 
measure and interpret; no 
reported external validation, 
only internal validation 
  Country Virus Period of data col-
lection  
Design Objective Outcomes Setting of data 
collection  






standard) and timing 
of Ebola virus con-
firmatory testing  
Limitations  
 Hartley et al (2017)32 Sierra  
Leone 
Ebola  December, 2014– 
November, 2015 
Observational retro-
spective study of data at 
admission 
Construct an easy-to-use 
and highly accurate triage 
scoring system that discrim-
inates Ebola virus infection 
risk in a malaria-sensitive 
manner and improve the 
predictive accuracy for 
Ebola virus disease and ma-
laria 
 Risk score            One Ebola virus 
treatment centre 
All ages 158/566  Quantitative PCR on 
admission; rapid di-
agnostic malaria test 
(histidine-rich pro-
tein-II antigen rapid 
diagnostic kits were 
used) 
Only the most prevalent 
symptoms at admission 
were included in the 
score; poor data quality; 
did not fully cover all the 
malaria season because 
the Ebola treatment centre 
was opened from Decem-
ber to June; recall bias 
 




Ebola  August, 2014– 
March, 2015  
Observational retro-
spective study of data at 
admission 
Refine the case definition 
and describe outcomes of 
admitted children  
Sensitivity and specificity of 
WHO case 
 subdefinitions 
11 Ebola holding 
units 
Paediatric popula-
tion (younger than 
13 years) 
309/1006 Quantitative PCR on 
admission 
Only included children 
younger than 13 years; 
oral plenary abstract; no 
reported external valida-
tion, only internal valida-
tion 
 
 Ingelbeen et al 
(2017)27 
Guinea Ebola  March, 2014– Sep-
tember, 2015 
Observational retro-
spective study of data at 
admission 
Describe the burden of non- 
cases in relation to the 
phase of the outbreak; deter-
mine the duration of their 
stay at the Ebola treatment 
centre and (potential) subse-
quent nosocomial infec-
tions; compare characteris-
tics, outcome, and risk fac-
tors for death in confirmed 
cases and non-cases to im-
prove the selection, diagno-
sis, and care of people with 
suspected Ebola virus dis-
ease 
Sensitivity and specificity of 
WHO case subdefinitions 
and symptoms on admission 
One Ebola treat-
ment centre 




Sunnyvale, CA USA) 
on admission 
The Ebola treatment cen-
tre for part of the outbreak 
was located within one 
hospital but then moved to 
another area in July; could 
not assess possible drivers 
for the large proportion of 
non- cases; no reported 
validation (internal or ex-
ternal) 
 
 Oza et al (2017)33 Sierra  
Leone 
Ebola November, 2014– 
March, 2015 
Observational retro-
spective study of data at 
admission 
Develop two Ebola risk 
scores to supplement the 
broad WHO case definition 
by further separating triaged 
patients based on their like-
lihood of being positive for 
Ebola virus  
Risk score  One Ebola treat-
ment centre 
All ages 252/424 Quantitative PCR on 
admission; biochem-
istry laboratory tests 
with the Piccolo 
Xpress (Abaxis, Un-
ion City, CA, USA) 
and i-STAT (Abbott 
Point of Care, Prince-
ton, NJ, USA) device 
Only one treatment centre; 
investigated 14 commonly 
recorded symptoms; small 
amount and poor quality 
of patient data; excluded 
exposure as a potential 
predictor because of large 
amount of missing data or 
poor data quality; patients 
might not be representa-
tive of the overall popula-
tion of suspect Ebola 
cases; no reported external 





  Country Virus Period of data col-
lection  
Design Objective Outcomes Setting of data 
collection  






standard) and timing 
of Ebola virus con-
firmatory testing  
Limitations  
 Hsu et al (2018)24 Guinea Ebola March– October, 
2014 
Observational retro-
spective study of sur-
veillance data 
Assess the diagnostic per-
formance of the WHO sus-
pected case definition by us-
ing epidemiological surveil-
lance and diagnostic test 
Sensitivity and specificity of 
WHO case definition, WHO 
case subdefinition, symp-
toms at admission, and epi-
demiological link 
National surveil-
lance line list 
All ages 1304/2847 Quantitative PCR (on 
admission and for de-
ceased patients at the 
community level) 
Unknown how representative 
the database was for all pa-
tients with Ebola virus dis-
ease; only 1412 patients had 
complete data to assess and 
analyse the WHO case defi-
nition; possible overestima-
tion of performance of WHO 
definition because only com-
mon symptoms were rec-
orded in the early stage of 
the outbreak; poor data qual-
ity; no reported validation 
(internal or external) 
 




Ebola August, 2014– 
March, 2015 
Observational retro-
spective study of data at 
admission 
Develop a predictive score 
that could be used to tailor 
the paediatric case defini-
tion for suspected Ebola vi-
rus disease according to the 
clinical and epidemiological 
setting 
Sensitivity and specificity of 
WHO case definition and 
risk score 
11 Ebola holding 
units 
Paediatric popula-
tion (younger than 
13 years) 
309/1006 Quantitative PCR on 
admission 
Only included children 
younger than 13 years; 
poor data quality; no data 
on the true Ebola status of 
people who did not meet 
the WHO case definition 
and were not admitted; no 
reported validation, only 
internal validation 
 
 Ingelbeen et al 
(2018)28 
Guinea Ebola March, 2014– Sep-
tember, 2015 
Observational retro-
spective study of data at 
admission 
Validate risk  
score by Oza and col-
leagues13 
Risk score One Ebola treat-
ment centre 
All ages 805/2311 Quantitative PCR on 
admission; Xpert 
Ebola Assay (Ce-
pheid GeneXpert) on 
admission 
Did not propose another 
algorithm; letter; no re-
ported external validation, 
only internal validation 
 




Ebola September, 2014– 
November, 2015 
Observational retro-
spective study of data at 
admission 
Evaluate the pre-existing 
health-care infrastructure 
during the Ebola virus dis-
ease outbreak, and assess 
the provided health care and 
safeguard functionality of a 
health-care system for all 
patients not suspected to 
have or diagnosed with 
Ebola virus disease 
Sensitivity and specificity of 
WHO case subdefinitions 
Screening at one 
hospital 
All ages 22/1556 Quantitative PCR on 
admission 
Scant description of data; 
poor data quality; no re-
ported validation (external 
or internal) 
 




Figure 2. HSROC summary of sensitivity and specificity 









Table 2. Sensitivity and specificity of WHO Ebola virus disease subdefinitions against reference standard of 
laboratory-confirmed Ebola virus infection, in decreasing order of sensitivity 
   
                                          WHO subdefinition                       Sensitivity (95% CI)      Specificity (95% CI) 
 
Positive predictive   
value (95% CI) 
Negative predictive 
value (95% CI) 
Huizenga et al (2019)6 WHO definition, with the difference 
that fever with sudden onset is not a 
mandatory criterion 
100·0% 42·5%* 2·4%* 100·0% 
Fitzgerald et al (2017)26 Contact alone, fever (in children 
older than 2 years) OR fever and 
conjunctivitis (in children younger 
than 2 years) 
94·0%* 35·0%* Not provided Not provided 
Roddy et al (2010)22 Epidemiological link or a combina-
tion of myalgia or arthralgia and any 
haemorrhage 
79·0% (64·0–91·0) 73·0% (60·0–84·0) Not provided Not provided 
Loubet et al (2016)31 WHO subdefinition 2 (temperature 
≥37·5°C plus risk factor†) 
75·0% (63·5–83·9) 62·3% (49·8–73·5) Not provided Not provided 
Roddy et al (2010)22 WHO case definition (clinical criteria 
only‡) 
73·0% (57·0–86·0) 43·0% (30·0–56·0) Not provided Not provided 
Roddy et al (2010)22 Fever plus three or more symptoms§ 68·0% (52·0–82·0) 46·0% (33·0–59·0) Not provided Not provided 
Loubet et al (2016)31 Temperature ≥38·5°C plus risk 
factor† 
68·4% (56·6–78·3) 82·6% (71·2–90·3) Not provided Not provided 
Arranz et al (2016)30 Contact and three symptoms§ 67·7% (51·3–84·2) 81·8% (70·4–93·2) 72·4% (56·1–88·7) 78·3% (66·3–90·2) 
Loubet et al (2016)31 WHO subdefinition 3 (temperature 
≥37·5°C plus clinical symptoms§) 
67·1% (55·2–77·2) 76·8% (64·8–85·8) Not provided Not provided 
Loubet et al (2016)31 WHO subdefinition 1 (risk factor plus 
clinical symptoms§) 
63·2% (51·3–73·7) 66·7% (54·2–77·3) Not provided Not provided 
Lado et al (2015)5 Three or more major symptomsfj 57·8% (52·1–61·4) 70·8% (64·7–76·4) 77·9% (73·1–82·3) 47·5% (42·3–52·7) 
Arranz et al (2016)30 Fever and three symptoms§ 58·1% (40·7–75·4) 50·0% (35·2–64·8) 45·0% (29·6–60·4) 62·9% (46·8–78·9) 
Hsu et al (2018)24 Clinical criteria§   57·2%* 62·0%* 66·4%* 52·5%* 
Ingelbeen et al (2017)27 WHO case definition (clinical criteria 
only||) 
 56·9%* 46·4%* 36·3%* 66·8%* 
Roddy et al (2010)22 Epidemiological link and two 
or  more general symptoms§ 
54·0% (37·0–70·0) 91·0% (80·0–97·0) Not provided Not provided 
Roddy et al (2010)22 Epidemiological link and three or 
more general symptoms§ 
54·0% (37·0–70·0) 93·0% (83·0–98·0) Not provided Not provided 
Arranz et al (2016)30 Contact plus fever 48·4% (30·8–66·0) 77·3% (64·9–89·7) 60·0% (40·8–79·2) 68·0% (55·1–80·9) 
Roddy et al (2010)22 Fever plus haemorrhage 44·0% (28·0–60·0) 72·0% (59·0–83·0) Not provided Not provided 
Ingelbeen et al (2017)27 Three major signs** 27·7%* 79·1%* 41·5%* 67·2%* 
Fitzgerald et al (2017)26 Contact, fever, and conjunctivitis OR 
contact, fever, anorexia, and two of 
abdominal pain, diarrhoea, or male 
sex (older than 2 years) 
23·0%* 97·0%* Not provided Not provided 
Kuehne et al (2015)23 History of contact, gastrointestinal 
symptoms†† and illness duration of 
>3 days 
20·0%* 94·4%* Not provided Not provided 
Hsu et al (2018)24 Unexplained death 14·2%* 92·8%* 72·0%* 45·2%* 
*95% CI not provided in the original paper. †For example, being a health worker, have attended a funeral, and having contact with a relative suspect of having Ebola virus. 
‡Fever plus three other symptoms or fever and haemorrhage. §Symptoms or criteria not specifed in original paper. fjThree or more symptoms among the following: intense 
fatigue, confusion, conjunctivitis, hiccups, diarrhoea, or vomiting. ||Acute fever and presenting three or more of the following: headache, anorexia or lack of appetite, lethargy, 
muscle or joint pain, breathing difficulties, vomiting, diarrhoea, stomach ache, difficulty swallowing, and hiccups; or any person with unexplained bleeding. 












































































































































































































































































NA NA 6 3 Y NA NA NA NA NA 3 4 1 2 Y NA 






NA NA NA NA NA NA NA NA 2 2 Y Y 1 NA 




NA NA 1 NA NA NA NA NA NA NA NA Y NA Y NA 3 
Fitzgerald et al (2018; 
paediatric population)25 
80%‡ NA NA 2 NA Y NA NA 1 2 Y 1 2 1 Y Y NA 




76%‡ NA 2 NA NA NA NA NA NA NA 1·5 NA Y Y Y NA 
Kuehne et al 
(2015)23 
53–59‡ NA NA + NA NA + + NA NA NA NA NA NA NA NA NA 
Roddy et al 
(2010)22 
‡ NA NA + NA NA NA NA NA NA NA Y Y Y + Y NA 
 














































































































































































































































































































Hartley et al 
(2017)32 






Y Y Y –1 –1 Y Y NA NA NA NA NA NA NA NA NA NA NA NA Y NA NA NA NA NA NA NA 
Loubet et al 
(2016)31 
Y 2 Y Y Y NA Y Y Y NA Y Y Y NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
Fitzgerald et al 
(2018; paediatric 
population)25 
Y 1 Y –1 1 –2 –1 –1 Y Y Y NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
Levine et al 
(2015)29 
Y 1 1 1 –1 NA Y Y Y Y NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 






NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
Roddy et al 
(2010)22 
+ Y + Y Y NA Y Y Y Y NA NA NA NA NA NA NA NA NA NA NA NA NA Y Y Y Y Y Y Y 
 
Predictive scores (numeric or + symbol) are shown in shaded cells (blue indicates positive scores and light pink indicates negative scores). Y indicates that the characteristic was assessed, but not used. AUC=area under the receiver operating characteristic curve. NA=not 
assessed. ORL=otorhinolaryngology. *Diarrhoea, vomiting, or anorexia or loss of appetite. †95% CI is taken from Ingelbeen et al (2018)28 because, although Oza and colleages do not report 95% CIs in their manuscript, Ingelbeen and colleagues have externally 
validated Oza and colleagues’ score and they do report the 95% CI. ‡95% CI, AUC, or both AUC and 95% CI not given in original paper. 
23 
 
Table 3. Sensitivity and specificity of fever, epidemiological link, or contact history, ordered by optimal 
performance 
 
                                        Variable                                                                                                            Sensitivity (95% CI)   Specificity (95% CI) 
 
 Fever cutoff     
 Loubet et al (2016)31 ≥38·5°C 80·2% (69·2–88·2) 82·6% (71·2–90·3)  
 Loubet et al (2016)31 ≥38·0°C 88·2% (78·2–94·1) 72·5% (60·2–82·2)  
 Loubet et al (2016)31 ≥37·5°C 93·4% (84·7–97·5) 50·7% (38·5–62·9)  
 Kuehne et al (2015)23 History of fever 85·3%* 26·4%*  
 Lado et al (2015)5 ≥37·5°C or referred 85·9% (82·4–89·0) 16·4% (12·0–21·6)  
 Arranz et al (2016)30 ≥38·0°C or referred 61·3% (44·1–78·4) 29·5% (16·1–43·0)  
 Roddy et al (2010)22 >38·0°C 85·0% (71·0–94·0) 20·0% (11·0–32·0)  
 Levine et al (2015)29 >38·0°C 85·0% (79·0–91·0) 21·0% (16·0–27·0)  
 Ingelbeen et al (2017)27 >38·0°C 71·5%* 30·5%*  
 Pooled analysis† >38·0°C 80·0% (69·0–90·0) 25·0% (17·0–33·0)  
 Epidemiological link     
 Hsu et al (2018)24 Contact with infected persons or body fluid, handling of bushmeat, attending the 
funeral of a patient with Ebola virus disease 
74·7%* 67·1%*  
 Roddy et al (2010)22 Epidemiological link‡ 67·0% (50·0–81·0) 86·0% (74·0–94·0)  
 Arranz et al (2016)30 History of contact with a person with confirmed Ebola virus disease 100·0% 59·0% (43·5–74·4)  
 Levine et al (2015)29 Sick contact§ 65·0% (58·0–73·0) 61·0% (54·0–67·0)  
 Loubet et al (2016)31 Health worker or having had contact with a person with suspected Ebola virus dis-
ease or having attended funerals 
81·5% (44·0–60·7) 29·0% (19·0–41·3)  
 Kuehne et al (2015)23 Contact to case 47·3%* 71·2%*  
 Lado et al (2015)5 Travel to an Ebola virus disease hotspot area, health-care work, funeral 
attendance, or contact with an ill family member or friendfj 
21·6% (17·9–25·6) 84·6% (79·6–88·8)  
 Optimal performance is the definition that achieved best balance between maximising sensitivity versus maximising specificity. *95% CI not provided in 
original paper. 
†The pooled analysis was used for the studies that had the same cut-off for fever (>38°C).22,27,29  ‡Epidemiological link was defined as direct contact with an 
individual potentially infected with Marburg haemorrhagic fever or his or her body fluids or direct contact during funeral practices. §Direct or indirect contact 
with a patient with suspected or confirmed Ebola virus disease in the previous 21 days, including living in the same household or providing direct care for the 
patient. fjA contact is any person who comes into contact with a case or suspected case by sleeping in the same household within the past month; direct 
physical contact with the case (dead or alive); touching his or her linens or body fluid; or attendance at a funeral of a person with confirmed or suspected 
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